Abstract
Comorbidities related to the cardiovascular system are one of the most prevalent in patients with acromegaly, and contribute to an increased risk of morbidity and all-cause mortality. Specifically, hypertension, cardiomyopathy, heart valve disease, arrhythmias, atherosclerosis, coronary artery disease, and cardiac dysfunction may be frequent findings. Although the underlying physiopathology for each comorbidity may not be fully elucidated, uncontrolled growth hormone/insulin-like growth factor 1 excess, age, prolonged disease duration, and coexistence of other cardio-vascular risk factors are significant influencing variables. A simple diagnostic approach to screen for the presence of these comorbidities may allow prompt treatment and arrest the progression of cardiac abnormalities. In this article, we revise the most prevalent cardiovascular comorbidities and their pathophysiology in acromegalic patients, and we address some recommendations for their prompt diagnosis, management and treatment. Strengths and pitfalls of different diagnostic techniques that are currently being used and how different treatments can affect these complications will be further discussed.
Similar content being viewed by others
References
I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)
S. Melmed, Medical progress: acromegaly. N. Engl. J. Med. 355, 2558–2573 (2006)
A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed; Acromegaly Consensus Group, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014)
R. López-Velasco, H.F. Escobar-Morreale, B. Vega, E. Villa, J.M. Sancho, J.L. Moya-Mur, R. García-Robles, Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J. Clin. Endocrinol. Metab. 82, 1047–1053 (1997)
C. Sardella, D. Cappellani, C. Urbani, L. Manetti, G. Marconcini, L. Tomisti, I. Lupi, G. Rossi, I. Scattina, M. Lombardi, Di Bello V, C. Marcocci, E. Martino, F. Bogazzi, Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur. J. Endocrinol. 175, 443–453 (2016)
G. Lombardi, A. Colao, P. Marzullo, D. Ferone, S. Longobardi, Esposito V, B. Merola, Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J. Endocrinol. 155(Suppl 1), S33–S37 (1997). discussion S39
O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61–67 (2008)
L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Endocrine Society: acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)
E. Ritvonen, E. Löyttyniemi, P. Jaatinen, T. Ebeling, L. Moilanen, P. Nuutila, R. Kauppinen-Mäkelin, C. Schalin-Jäntti, Mortality in acromegaly: a 20-year follow-up study. Endocr. Relat. Cancer 23, 469–480 (2015)
A. Ramos-Levi, M. Marazuela, Sleep apnea syndrome in acromegalic patients: can morphological evaluation guide us to optimize treatment? Endocrine. 51, 203–204 (2016)
A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25, 102–152 (2004)
M.S.1 Broder, M.P. Neary, E. Chang, D. Cherepanov, L. Katznelson, Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17, 333–341 (2014)
M. Bondanelli, M.R. Ambrosio, E.C. degli Uberti, Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 4, 239–249 (2001)
F. Costenaro, A. Martin, R.F. Horn, M.A. Czepielewski, T.C. Rodrigues, Role of ambulatory blood pressure monitoring in patients with acromegaly. J. Hypertens. 34, 1357–1363 (2016)
G. Vitale, R. Pivonello, R.S. Auriemma, E. Guerra, F. Milone, S. Savastano, G. Lombardi, A. Colao, Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. 63, 470–476 (2005)
A.S. Powlson, M. Gurnell, Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 103, 75–85 (2016)
G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab. 87, 3174–3179 (2002)
M. Terzolo, C. Matrella, A. Boccuzzi, S. Luceri, M. Borriero, G. Reimondo, A. Pia, E. Rovero, P. Paccotti, A. Angeli, Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J. Endocrinol. Invest. 22, 48–54 (1999)
C. Sardella, C. Urbani, M. Lombardi, A. Nuzzo, L. Manetti, I. Lupi, G. Rossi, S. Del Sarto, I. Scattina, V. Di Bello, E. Martino, F. Bogazzi, The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin. Endocrinol. 81, 573–581 (2014)
A.E. Schutte, M. Volpe, G. Tocci, E. Conti, Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension. 63, 1070–1077 (2014)
P. Kamenicky, S. Viengchareun, A. Blanchard, G. Meduri, P. Zizzari, M. Imbert-Teboul, A. Doucet, P. Chanson, M. Lombès, Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149, 3294–3305 (2008)
P. Kamenicky, A. Blanchard, M. Frank, S. Salenave, A. Letierce, M. Azizi, M. Lombès, P. Chanson, Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 96, 2127–2135 (2011)
D. Rizzoni, E. Porteri, A. Giustina, C. De Ciuceis, I. Sleiman, G.E. Boari, M. Castellano, M.L. Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei, Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 43, 561–565 (2004)
A.K. Annamalai, A. Webb, N. Kandasamy, M. Elkhawad, S. Moir, F. Khan, K. Maki-Petaja, E.L. Gayton, C.H. Strey, S. O’Toole, S. Ariyaratnam, D.J. Halsall, A.N. Chaudhry, L. Berman, D.J. Scoffings, N.M. Antoun, D.P. Dutka, I.B. Wilkinson, J.M. Shneerson, J.D. Pickard, H.L. Simpson, M. Gurnell, A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040–1050 (2013)
T.K. Hansen, J. Møller, K. Thomsen, E. Frandsen, R. Dall, J.O. Jørgensen, J.S. Christiansen, Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am. J. Physiol. Endocrinol. Metab. 281, 1326–1332 (2001)
F. Bogazzi, M. Lombardi, E. Strata, G. Aquaro, V. Di Bello, C. Cosci, C. Sardella, E. Talini, E. Martino, High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin. Endocrinol. 68, 361–368 (2008)
A. Colao, R. Baldelli, P. Marzullo, E. Ferretti, D. Ferone, P. Gargiulo, M. Petretta, G. Tamburrano, G. Lombardi, A. Liuzzi, Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 85, 193–199 (2000)
A. Colao, P. Marzullo, C. Di Somma, G. Lombardi, Growth hormone and heart. Clin. Endocrinol. (Oxf). 54, 137–154 (2001)
N.S. Freestone, S. Ribaric, W.T. Mason, The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol. Cell. Biochem. 163–164, 223–229 (1996)
H. Gouya, O. Vignaux, P. Le Roux, P. Chanson, J. Bertherat, X. Bertagna, P. Legmann, Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. Am. J. Roentgenol. 190, 1576–1582 (2008)
L. Saccà, R. Napoli, A. Cittadini, Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin. Endocrinol. 59, 660–671 (2003)
H. Bihan, C. Espinosa, H. Valdes-Socin, S. Salenave, J. Young, S. Levasseur, P. Assayag, A. Beckers, P. Chanson, Long-term outcome of patients with acromegaly and congestive heart failure. J. Clin. Endocrinol. Metab. 89, 5308–5313 (2004)
M. Losa, K. von Werder, The heart in acromegaly. Growth Hormone and the Heart. A. Giustina (ed.) Kluwer Academic, Boston, 2001, 33–43
J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)
A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M. Giraldo, A.C. Pinedo, D.P. Guerrero, C.A. Barrera, H.I. Franco, A. Ribeiro-Oliveira Jr, L. Vilar, R.S.12 Jallad, F.G. Duarte, M. Gadelha, C.L. Boguszewski, J. Abucham, L.A. Naves, N.R. Musolino, M.E. de Faria, C. Rossato, M.D. Bronstein, Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 19, 448–457 (2016)
A.M. Pereira, S.W. van Thiel, J.R. Lindner, F. Roelfsema, E.E. van der Wall, H. Morreau, J.W. Smit, J.A. Romijn, J.J. Bax, Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89, 71–75 (2004)
A. Colao, L. Spinelli, P. Marzullo, R. Pivonello, M. Petretta, C. Di Somma, G. Vitale, D. Bonaduce, G. Lombardi, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88, 3196–3201 (2003)
A.A. van der Klaauw, J.J. Bax, F. Roelfsema, G.B. Bleeker, E.R. Holman, E.P. Corssmit, E.E. van der Wall, J.W. Smit, J.A. Romijn, A.M. Pereira, Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm. IGF. Res. 16, 101–107 (2006)
A.A. van der Klaauw, J.J. Bax, J.W. Smit, E.R. Holman, V. Delgado, G.B. Bleeker, N.R. Biermasz, F. Roelfsema, J.A. Romijn, A.M. Pereira, Increased aortic root diameters in patients with acromegaly. Eur. J. Endocrinol. 159, 97–103 (2008)
G. Kahaly, K.V. Olshausen, S. Mohr-Kahaly, R. Erbel, S. Boor, J. Beyer, J. Meyer, Arrhythmia profile in acromegaly. Eur. Heart J. 13, 51–56 (1992)
S. Mosca, S. Paolillo, A. Colao, E. Bossone, A. Cittadini, F.L. Iudice, A. Parente, S. Conte, G. Rengo, D. Leosco, B. Trimarco, P.P. Filardi, Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int. J. Cardiol. 167, 1712–1718 (2013)
P. Maffei, C. Martini, A. Milanesi, A. Corfini, R. Mioni, E. de Carlo, C. Menegazzo, M. Scanarini, R. Vettor, G. Federspil, N. Sicolo, Late potentials and ventricular arrhythmias in acromegaly. Int. J. Cardiol. 104, 197–203 (2005)
A. Kırış, C. Erem, O.E. Turan, N. Civan, G. Kırış, I. Nuhoğlu, A. Ilter, H.O. Ersöz, M. Kutlu, Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 44, 200–206 (2013)
L. Warszawski, L. Kasuki, R. Sá, C.M. Dos Santos Silva, I. Volschan, I. Gottlieb, R.C. Pedrosa, M.R. Gadelha, Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19, 582–589 (2016)
A. Colao, S. Spiezia, G. Cerbone, R. Pivonello, P. Marzullo, D. Ferone, C. Di Somma, A.P. Assanti, G. Lombardi, Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol. 54, 515–524 (2001)
I. Kartal, H. Oflaz, B. Pamukçu, M. Meriç, F. Aral, N. Ozbey, F. Alagöl, Investigation of early atherosclerotic changes in acromegalic patients. Int. J. Clin. Pract. 64, 39–44 (2010)
A.N. Paisley, M. Banerjee, M. Rezai, R.E. Schofield, S. Balakrishnannair, A. Herbert, J.A. Lawrance, P.J. Trainer, J.K. Cruickshank, Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab. 96, 1486–1492 (2011)
M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel--the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)
M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. López-Félix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99, 4438–4446 (2014)
O. Dupuy, T. Petrossian, L. Bordier, H. Mayaudon, B. Bauduceau, Registre de L’Acromégalie. Hypertension and acromegaly in the elderly: French registry data. Arch. Mal. Coeur. Vaiss. 100, 660–663 (2007)
S. Cannavo, B. Almoto, G. Cavalli, S. Squadrito, G. Romanello, M.T. Vigo, F. Fiumara, S. Benvenga, F. Trimarchi, Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab. 91, 3766–3772 (2006)
F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, P. Pepe, F. Falaschi, G. Mariani, E.50H. Martino, J. Akutsu, G. Kreutzer, D. Wasmeier, C. Ropers, M. Rost, Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)
H. Akutsu, J. Kreutzer, G. Wasmeier, D. Ropers, C. Rost, M. Möhlig, H. Wallaschofski, M. Buchfelder, C. Schöfl, Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 162, 879–886 (2010)
A. Giustina, F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J.A. Wass, S. Melmed, Diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26, 1242–1247 (2003)
S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013)
G. Minniti, M.L. Jaffrain-Rea, C. Moroni, R. Baldelli, E. Ferretti, R. Cassone, A. Gulino, G. Tamburrano, Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin. Endocrinol. 49, 101–106 (1998)
A. Colao, L. Spinelli, A. Cuocolo, S. Spiezia, D. Bonaduce, M. Salvatore, G. Lombardi, Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endoccrinol. Metab. 87, 3097–3104 (2002)
M. Galderisi, G. Vitale, A. Bianco, R. Pivonello, G. Lombardi, Divitiis Od, Colao A, Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly. Clin. Endocrinol. 64, 390–397 (2006)
L. Spinelli, M. Petretta, G. Verderame, G. Carbone, A.A. Venetucci, A. Petretta, W. Acampa, D. Bonaduce, A. Colao, A. Cuocolo, Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J. Clin. Endocrinol. Metab. 88, 4105–1409 (2003)
C.M. dos Santos Silva, I. Gottlieb, I. Volschan, L. Kasuki, L. Warszawski, G.A. Balarini Lima, S.S. Xavier, R.C. Pedrosa, L.V. Neto, M.R. Gadelha, Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort. J. Clin. Endocrinol. Metab. 100, 4447–4455 (2015)
J.M. Dekker, E.G. Schouten, P. Klootwijk, J. Pool, D. Kromhout, Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation 90, 779–785 (1994)
M. Unubol, U. Eryilmaz, E. Guney, M. Ture, C. Akgullu, QT dispersion in patients with acromegaly. Endocrine 43, 419–423 (2013)
H. Baser, N. Akar Bayram, B. Polat, B. Evranos, R. Ersoy, E. Bozkurt, B. Cakir, The evaluation of QT intervals during diagnosis and after follow-up in acromegaly patients. Acta Med. Port. 27, 428–432 (2014)
M. Dural, G. Kabakci, N. Cinar, T. Erbaş, U. Canpolat, K.M. Gürses, L. Tokgözoğlu, A. Oto, E.B. Kaya, H. Yorgun, L. Sahiner, S. Dağdelen, K. Aytemir, Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly. Pituitary 17, 163–170 (2014)
A. Colao, The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin. Endocrinol. 69, 347–358 (2008)
M. Yaron, E. Izkhakov, J. Sack, I. Azzam, E. Osher, K. Tordjman, N. Stern, Y. Greenman, Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors. Pituitary 19, 322–331 (2016)
T.D. Bradley, J.S. Floras, Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 373, 82–93 (2009)
M.1 Stelmachowska-Banaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45, 328–334 (2011)
A.M. Ramos-Leví, I. Bernabeu, C. Álvarez-Escolá, J. Aller, T. Lucas, P. de Miguel, L. Rodríguez-Cañete, M.A. Sampedro-Núñez, I. Halperin, M. Puig-Domingo, M. Marazuela, Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin. Endocrinol. 84, 540–550 (2016)
L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011. update. Endocr. Pract. 17(Suppl 4), 1–44 (2011)
A. Colao, P. Marzullo, A. Cuocolo, L. Spinelli, R. Pivonello, D. Bonaduce, M. Salvatore, G. Lombardi, Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol. 58, 169–176 (2003)
A. Colao, Long-term acromegaly and associated cardiovascular complications: a case-based review. Best Pract. Res. Clin. Endocrinol. Metab. 23(Suppl 1), S31-8 (2009)
G. Minniti, C. Moroni, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, C. Affricano, C. Cantore, G. Tamburrano, R. Cassone, Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin. Endocrinol. 55, 307–313 (2001)
A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A.M. Della Morte, R. Pivonello, M. Salvatore, G. Lombardi, Is the acromegalia cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86, 1551–1557 (2001)
A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, G. Lombardi, Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J. Clin. Endocrinol. Metab. 85, 3132–3140 (2000)
P. Maison, A.I. Tropeano, I. Macquin-Mavier, A. Giustina, P. Chanson, Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 92, 1743–1747 (2007)
L. De Marinis, A. Bianchi, G. Mazziotti, M. Mettimano, D. Milardi, A. Fusco, V. Cimino, G. Maira, A. Pontecorvi, A. Giustina, The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11, 13–20 (2008)
A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15, 50–58 (2012)
G. Lombardi, A. Colao, P. Marzullo, B. Biondi, E. Palmieri, S. Fazio, Multicenter Italian study group on Lanreotide: improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J. Endocrinol. Invest. 25, 971–976 (2002)
L.M. Fatti, M. Scacchi, E. Lavezzi, F. Pecori Giraldi, M. De Martin, P. Toja, G. Michailidis, M. Stramba-Badiale, F. Cavagnini, Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin. Endocrinol. 65, 626–630 (2006)
A. Colao, J. Marek, M.I. Goth, P. Caron, J.M. Kuhn, F.M. Minuto, N.J. Weissman, No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93, 2243–2248 (2008)
C. Erem, H.O. Ersöz, K. Ukinç, A.M. Avunduk, A. Hacihasanoglu, M. Koçak, Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30, 145–149 (2006)
C.B.1 Vianna, M.L. Vieira, C. Mady, B. Liberman, A.E. Durazzo, M. Knoepfelmacher, L.R. Salgado, J.A. Ramires, Treatment of acromegaly improves myocardial abnormalities. Am. Heart J. 143, 873–876 (2002)
W.H. Smith, R.U. Nair, D. Adamson, M.T. Kearney, S.G. Ball, A.J. Balmforth, Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J. Endocrinol. 187, 379–386 (2005)
A. Colao, P. Cappabianca, P. Caron, E. De Menis, A.J. Farrall, M.R. Gadelha, A. Hmissi, A. Rees, M. Reincke, M. Safari, G. T’Sjoen, H. Bouterfa, R.C. Cuneo, Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. 70, 757–768 (2009)
A. Colao, R. Pivonello, M. Galderisi, P. Cappabianca, R.S. Auriemma, M. Galdiero, L.M. Cavallo, F. Esposito, G. Lombardi, Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metab. 93, 2639–2646 (2008)
A. Colao, R.S. Auriemma, M. Galdiero, G. Lombardi, R. Pivonello, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94, 3746–3756 (2009)
G. Tolis, N.G. Angelopoulos, E. Katounda, G. Rombopoulos, V. Kaltzidou, D. Kaltsas, A. Protonotariou, A. Lytras, Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. J. Neuroendocrinol. 83, 249–257 (2006)
E. Couture, V. Bongard, J.C. Maiza, A. Bennet, P. Caron, Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15, 518–525 (2012)
R. Baldelli, C. Battista, F. Leonetti, M.R. Ghiggi, M.C. Ribaudo, A. Paoloni, E. D’Amico, E. Ferretti, R. Baratta, A. Liuzzi, V. Trischitta, G. Tamburrano, Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. 59, 492–429 (2003)
M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes Endocrinol. 2, 875–884 (2014)
A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard, Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)
A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154, 467–477 (2006)
C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jöckel, S. Möhlenkamp, R. Erbel, B. Saller, K. Mann, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95, 3648–3656 (2010)
R. Pivonello, M. Galderisi, R.S. Auriemma, M.C. De Martino, M. Galdiero, A. Ciccarelli, A. D’Errico, I. Kourides, P. Burman, G. Lombardi, A. Colao, Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J. Clin. Endocrinol. Metab. 92, 476–482 (2007)
M.C. De Martino, R.S. Auriemma, G. Brevetti, G. Vitale, V. Schiano, M. Galdiero, L. Grasso, G. Lombardi, A. Colao, R. Pivonello, The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J. Endocrinol. Invest. 33, 663–670 (2010)
E. Kuhn, L. Maione, A. Bouchachi, M. Rozière, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173, 693–702 (2015)
R.S. Auriemma, R. Pivonello, M.C. De Martino, G. Cudemo, L.F. Grasso, M. Galdiero, Y. Perone, A. Colao, Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur. J. Endocrinol. 168, 15–22 (2012)
R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine (2016 Jun 13). doi:10.1007/s12020-016-0995-5
R. Luboshitzky, D. Barzilai, Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome. JAMA 244, 1825–1827 (1980)
L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)
M. Marazuela, A. Ramos-Leví, M. Sampedro-Núñez, I. Bernabeu, Cabergoline treatment in acromegaly: pros. Endocrine 46, 215–219 (2014)
L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714–E1719 (2012)
L. Kasuki, L. Vieira Neto, M.R. Gadelha, Cabergoline treatment in acromegaly: cons. Endocrine. 46, 220–225 (2014)
A. Baldwin, T. Cundy, J. Butler, A.D. Timmis, Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta. Endocrinol. 100, 581–587 (1985)
J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, P.M. Stewart, A.S. Bates, Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89, 1613–1617 (2004)
G. Ntali, N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. North. Am. 44, 117–126 (2015)
Funding and Acknowledgments
This work has not received specific grants or funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
ARL has received lecture fees from Ipsen and Novartis. MM has received lecture fees, advisor fees and research grants from Pfizer and lecture fees from Novartis and Ipsen. The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Ramos-Leví, A.M., Marazuela, M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 55, 346–359 (2017). https://doi.org/10.1007/s12020-016-1191-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1191-3